Under the collaboration, Lilly will in-license a portfolio of branded generic injectable and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab based in Bangalore, India.
The collaboration will allow Agila Specialties to manufacture medicines and Lilly to register and market the medications across the emerging markets.
Lilly, in addition to the initial 10 medicines included as part of the agreement, also has the right to increase additional branded generic oncology products to the portfolio in the future.
Lilly senior vice president and emerging markets division president Jacques Tapiero said, ”Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets."
Strides Arcolab founder and group CEO Arun Kumar said, "We are delighted to partner with Lilly to expand its branded generics platform with high-quality oncology products that will benefit from Lilly’s strong global presence in key markets."
Commenting on the tie up, Lilly India managing director Melt Van Der Spuy said the partnership marks Lilly India’s entry into branded generics.